This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

"Anti-Aging" Pill Manufacturer SeroVital Sues Amazon For "Bait And Switch" Advertising

NEW YORK, March 7, 2013 /PRNewswire/ -- SanMedica International, LLC, SeroVital™-hgh's distributor, has filed a lawsuit against the web giant Amazon, charging the company with false advertising and "bait and switch" tactics.

The introduction to the lawsuit explains, "SeroVital is a patent-pending dietary supplement that has been shown in a double-blind, placebo-controlled study to promote the human body's natural production of serum human growth hormone levels by a mean over baseline of over 600%. Although there are many products that claim to assist the body in producing growth hormone, SeroVital is unique, because only it has been shown to be effective for both men and women of a wide age range."

In the lawsuit, SanMedica International alleges Amazon is using its unique, research-backed product and recognizable name to "bait" customers into clicking on ads, but is then offering them a completely different product that lacks SeroVital's clinical backing. The claim reads: "Defendant [Amazon] thus capitalizes on the goodwill of Plaintiff's [SanMedica's] scientifically supported product and carefully-developed intellectual property in order to 'bait' people searching for Plaintiff's product on the internet into viewing Defendant's website, where Defendant is then able to 'switch' the product purportedly being offered to products other than those marketed and sold by Plaintiff… This is a classic bait and switch case."

The suit was filed yesterday in the United States District Court for the District of Utah (Case Number 2:13-CV-00169) by the law firm Price Parkinson & Kerr, PLLC, who is clearly pulling no punches when going after Amazon. The lawsuit calls Amazon's actions "especially nefarious," saying, "it is using the name of SeroVital, which is scientifically substantiated, to sell products that lack scientific support for their claims." The suit also claims Amazon "continues to falsely advertise SeroVital for sale as alleged above and to infringe on Plaintiff's trademark by using that trademark in advertisements placed through search engine providers in a manner likely to cause confusion, mistake or to deceive the public."

When questioned about the lawsuit, Jason Kerr — lead attorney on the case for Price, Parkinson & Kerr, would only answer, "No comment." But Chantelle Daines, spokesperson for SanMedica International, said, "We have worked very hard to ensure the integrity of our product, SeroVital-hgh, and we refuse to allow other companies to use our reputation for their own gain. This is not only an infringement on our investment, but is misleading to potential customers who may think they're buying a product backed by SeroVital's serious research, but are not."

SOURCE SeroVital

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.99 -0.02%
FB $99.54 -0.21%
GOOG $678.11 -0.68%
TSLA $148.25 0.18%
YHOO $26.82 -0.85%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs